About us

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany.

The company is developing highly innovative immunotherapies to target various forms and stages of cancer.

Medigene concentrates on the development of personalized T cell-based therapies with the focus on T cell-receptor modified T cells (TCR-Ts) and has associated projects currently in pre-clinical and clinical development.

For more information, please visit http://medigene.com

Products and services

Medigene’s TCR-T pipeline is being built to contain a collection of TCR-Ts that recognize different antigens which are expressed by various types of tumor.

Upon completion, Medigene’s TCR-T pipeline will enable individuals of diverse patient populations to be matched for the treatment with TCR-Ts according to their MHC molecules and specificities for antigens expressed by tumor cells.

The pipeline is built by natural TCR-Ts with optimal affinities that can be expressed in CD4+ or CD8+ cells, selected by their specificities.

Medigene's DC vaccines: The scientific team of Medigene has developed new, fast and efficient methods for generating autologous (patient-specific) mature dendritic cells which have the relevant characteristics to generate very strong T cell and NK cell immune responses.

The dendritic cells can be loaded with various tumor antigens to treat different forms of cancer.

Medigene's Immunotherapy Pipeline

Medigene is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The company concentrates on the development of personalized T cell-based immunotherapies.

Further reading

Medigene AG
Lochhamer Str. 11
82152 Martinsried

Phone: +49 89 2000330
Internet: www.medigene.com
E-mail: Send message

Contact person

Kerstin Pino Tossi
Manager Business Development
Phone: +49 89 2000333306
E-mail: Send message

News & Innovations

Medigene publishes topline interim data from ongoing Phase I/II clinical trial with DC vaccines in AML patients
  • Topline-data from first half of treatment period (one year)

  • Very good feasibility of the manufacture of the vaccine from patient-derived cells

  • Excellent safety and tolerability profile

  • Preliminary data on overall survival and progression-free survival

  • Presentation of further details planned at an upcoming scientific conference

Further reading

Click here if you notice an image that violates copyright or privacy rights.

Get in contact

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection